Project Grant R21AI184196
Award Date
8/1/24
Completion Date
6/30/26
Dollars Obligated
$408K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $781,367 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Weill Medical College of Cornell University. The grant, awarded on January 25, 2024, will support research to define and maximize the impact of CD8+ T-cell selection on the landscape of HIV integration sites. The goal is to optimize strategies for eradicating the persistent reservoir of HIV-infected cells and achieve...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $681,278 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant, which runs from July 2024 to May 2026, will fund research to characterize the HIV latent reservoir and model the contributions of antigen-driven and homeostatic proliferation to its persistence in people living with HIV on antiretroviral therapy. The goal is to help design future HIV...
The University of California, Irvine was awarded a $228,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, effective January 2, 2025 through December 31, 2026, supports research to identify novel antiviral functions of the APOBEC3B enzyme that do not require its deaminase activity. The goal is to understand how APOBEC3B modulates the PKR signaling pathway to promote...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $502,861 to the University of California, San Diego (UCSD) to investigate the role of the PCIF1 protein and its effects on RNA modification in the context of HIV infection. The key objectives are to: Define the dynamics and mapping of human m6Am RNA methylome in response to HIV infection and methamphetamine exposure....
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $220,224.00 to the University of Chicago to computationally investigate key morphological transitions in the HIV-1 life cycle. The research aims to improve understanding of the assembly and disassembly processes involved in HIV-1 infection, including virion budding, viral core maturation, and capsid uncoating. This...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $227,018 to the University of California, Irvine (UCI) from May 1, 2025 to April 30, 2027. The project aims to determine the role of microglia, brain-resident immune cells, in defending against Toxoplasma gondii infection in the context of AIDS-associated immune deficiency. Key objectives include examining...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $7,105,240 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, Davis. This 5-year grant, effective December 17, 2024, will support the development of an HIV vaccine regimen that elicits cooperative interactions between env fusion peptide-directed antibodies and follicle-homing helper and cytotoxic T cells. The grant program, titled "OPTIMAL T-CELL...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $411,840 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Illinois to develop a computational toolkit for systematically dissecting protein drug resistance mechanisms against HIV. The goal is to leverage protein conformational dynamics to enable the rational design of effective counterstrategies to combat HIV drug resistance. The 2-year project will involve...